🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. TAK-954 Placebo

    Takeda

    Postoperative Gastrointestinal Dysfunction

    phase 2 small molecule completed

    1 trial

  2. TAK-981

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule completed

    1 trial

  3. TAK-981

    Takeda

    Lymphoma, Non-Hodgkin

    phase 2 small molecule terminated

    1 trial

  4. TAK-981

    Takeda

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  5. TAK-981

    Takeda

    Relapsed and/or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule terminated

    1 trial

  6. TAK-994

    Takeda

    Narcolepsy Type 1 (NT 1)

    phase 2 small molecule terminated

    1 trial

  7. TAK-994

    Takeda

    Narcolepsy Type 1 (NT1)

    phase 2 small molecule terminated

    1 trial

  8. TAK228

    Takeda

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  9. TD-8954

    Takeda

    Enteral Feeding Intolerance

    phase 2 small molecule completed

    1 trial

  10. TDV

    Takeda

    Healthy

    phase 2 mab completed

    1 trial

  11. TDV Liquid Formulation 1

    Takeda

    Dengue Fever

    phase 2 small molecule completed

    1 trial

  12. TIMP-GLIA

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    2 trials

  13. Tak-228 & Tak-117

    Takeda

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

    Takeda

    Dengue Fever

    phase 2 mab completed

    2 trials

  15. Teduglutide

    Takeda

    Postoperative Fistula

    phase 2 small molecule completed

    1 trial

  16. Teduglutide (ALX-0600)

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  17. Tislelizumab

    Takeda

    Minimal Residual Disease

    phase 2 small molecule active

    1 trial

  18. Udenafil

    Takeda

    Erectile Dysfunction

    phase 2 small molecule terminated

    2 trials

  19. VP20621

    Takeda

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  20. Vedolizumab

    Takeda

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 2 small molecule completed

    2 trials

  21. Vedolizumab

    Takeda

    Collagenous Gastritis

    phase 2 mab active

    1 trial

  22. Vedolizumab

    Takeda

    Celiac Disease

    phase 2 small molecule terminated

    1 trial

  23. Vedolizumab 300 MG Injection [Entyvio]

    Takeda

    Immune Checkpoint Inhibitor-Related Colitis

    phase 2 small molecule active

    1 trial

  24. Vedolizumab intravenous injection

    Takeda

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources